Abstract: Objective: To evaluate the efficacy and safety of low-dose apatinib in treating reactive cutaneous capillary endothelial proliferation (RCCEP) induced by camrelizumab. Methods: RCCEP incidence was retrospectively analyzed in 140 patients with advanced solid tumors treated with different types of antiangiogenic drugs combined with camrelizumab. The efficacy and safety of 125 and 250 mg apatinib were analyzed for treating camrelizumab-induced RCCEP in 50 patients with advanced solid tumors. Results: RCCEP incidence in 140 patients with advanced solid tumors treated with camrelizumab combined with different types of antiangiogenic drugs was retrospectively analyzed. The results showed that the incidence of camrelizumab-induced RCCEP in the bevacizumab, anlotinib, fruquintinib, regofinib, and apatinib groups was 93.3%, 72.7%, 47.6%, 70.6%, and 14.0%, respectively. Apatinib significantly reduced RCCEP incidence compared with other antiangiogenic drugs: bevacizumab group vs. apatinib group (P<0.000 1); anlotinib group vs. apatinib group (P<0.0001); fruquintinib group vs. apatinib group (P=0.005); and regofinib group vs. apatinib group (P<0.000 1). The efficacy and safety of different low-dose apatinib were observed in 50 patients with RCCEP and advanced solid tumors. The total effective rate of 250 mg apatinib was 97.6% when treating 42 patients with RCCEP, while that of 125 mg apatinib was 87.5% when treating eight patients with RCCEP. There were no ≥grade 3 treatment-related adverse events in both patient groups treated with 125 and 250 mg apatinib. Conclusions: Apatinib could significantly reduce the incidence of camrelizumab-induced RCCEP compared with other antiangiogenic drugs. Low-dose apatinib could effectively and safely alleviate RCCEP.